학술논문
SARS-CoV-2 testing, positivity, and factors associated with COVID-19 among people with HIV across Europe in the multinational EuroSIDA cohort.
Document Type
Academic Journal
Author
Fursa O; Centre of Excellence for Health, Immunity and Infections, Rigshospitalet, Copenhagen, Denmark.; Bannister W; Centre of Excellence for Health, Immunity and Infections, Rigshospitalet, Copenhagen, Denmark.; Neesgaard B; Centre of Excellence for Health, Immunity and Infections, Rigshospitalet, Copenhagen, Denmark.; Podlekareva D; Centre of Excellence for Health, Immunity and Infections, Rigshospitalet, Copenhagen, Denmark.; Department of Respiratory and Infectious Diseases, Bispebjerg Hospital, University of Copenhagen, Copenhagen, Denmark.; Kowalska J; Department of Adults' Infectious Diseases, Medical University of Warsaw, Warsaw, Poland.; Benfield T; Department of Infectious Diseases, Copenhagen University Hospital-Amager and Hvidovre, Hvidovre, Denmark.; Gerstoft J; Department of Infectious Diseases, Rigshospitalet, Copenhagen, Denmark.; Reekie J; Centre of Excellence for Health, Immunity and Infections, Rigshospitalet, Copenhagen, Denmark.; Rasmussen LD; Department of Infectious Diseases, Odense University Hospital, Odense, Denmark.; Aho I; Division of Infectious Diseases, Helsinki University Hospital, Helsinki, Finland.; Guaraldi G; Modena HIV Cohort, Università degli Studi di Modena, Modena, Italy.; Staub T; Centre Hospitalier de Luxembourg, Service des Maladies Infectieuses, Luxembourg City, Luxembourg.; Miro JM; Infectious Diseases Service, Hospital Clínic-IDIBAPS, University of Barcelona, Barcelona, Spain.; CIBERINFEC, Instituto de Salud Carlos III, Madrid, Spain.; Laporte JM; Hospital Universitario de Alava, Vitoria-Gasteiz, Spain.; Elbirt D; Allergy, Immunology and HIV Unit, Kaplan Medical Center, Rehovot, Israel.; Trofimova T; Novgorod Centre for AIDS prevention and control, Veliky Novgorod, Russian Federation.; Sedlacek D; Department of Infectious Diseases and Travel Medicine, Medical Faculty and Teaching Hospital Plzen, Charles University Prague, Plzen, Czech Republic.; Matulionyte R; Department of Infectious Diseases and Dermatovenerology, Faculty of Medicine, Vilnius University, Vilnius, Lithuania.; Vilnius University Hospital, Vilnius, Lithuania.; Oprea C; Victor Babes Clinical Hospital for Infectious and Tropical Diseases, Carol Davila University of Medicine and Pharmacy, Bucharest, Romania.; Bernasconi E; Division of Infectious Diseases, Ente Ospedaliero Cantonale Lugano, University of Geneva and University of Southern Switzerland, Lugano, Switzerland.; Hadžiosmanović V; Infectious Diseases Clinic, Clinical Center University of Sarajevo, Sarajevo, Bosnia and Herzegovina.; Mocroft A; Centre of Excellence for Health, Immunity and Infections, Rigshospitalet, Copenhagen, Denmark.; UCL Centre for Clinical Research, Epidemiology, Modelling and Evaluation (CREME), London, UK.; Peters L; Centre of Excellence for Health, Immunity and Infections, Rigshospitalet, Copenhagen, Denmark.
Source
Publisher: Wiley Country of Publication: England NLM ID: 100897392 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1468-1293 (Electronic) Linking ISSN: 14642662 NLM ISO Abbreviation: HIV Med Subsets: MEDLINE
Subject
Language
English
Abstract
Background: Although people with HIV might be at risk of severe outcomes from infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2; coronavirus 2019 [COVID-19]), regional and temporal differences in SARS-CoV-2 testing in people with HIV across Europe have not been previously described.
Methods: We described the proportions of testing, positive test results, and hospitalizations due to COVID-19 between 1 January 2020 and 31 December 2021 in the EuroSIDA cohort and the factors associated with being tested for SARS-CoV-2 and with ever testing positive.
Results: Of 9012 participants, 2270 (25.2%, 95% confidence interval [CI] 24.3-26.1) had a SARS-CoV-2 polymerase chain reaction test during the study period (range: 38.3% in Northern to 14.6% in Central-Eastern Europe). People from Northern Europe, women, those aged <40 years, those with CD4 cell count <350 cells/mm3 , and those with previous cardiovascular disease or malignancy were significantly more likely to have been tested, as were people with HIV in 2021 compared with those in 2020. Overall, 390 people with HIV (4.3%, 95% CI 3.9-4.8) tested positive (range: 2.6% in Northern to 7.1% in Southern Europe), and the odds of testing positive were higher in all regions than in Northern Europe and in 2021 than in 2020. In total, 64 people with HIV (0.7%, 95% CI 0.6-0.9) were hospitalized, of whom 12 died. Compared with 2020, the odds of positive testing decreased in all regions in 2021, and the associations with cardiovascular disease, malignancy, and use of tenofovir disoproxil fumarate disappeared in 2021. Among study participants, 58.9% received a COVID-19 vaccine (range: 72.0% in Southern to 14.8% in Eastern Europe).
Conclusions: We observed large heterogeneity in SARS-CoV-2 testing and positivity and a low proportion of hospital admissions and deaths across the regions of Europe.
(© 2024 The Authors. HIV Medicine published by John Wiley & Sons Ltd on behalf of British HIV Association.)
Methods: We described the proportions of testing, positive test results, and hospitalizations due to COVID-19 between 1 January 2020 and 31 December 2021 in the EuroSIDA cohort and the factors associated with being tested for SARS-CoV-2 and with ever testing positive.
Results: Of 9012 participants, 2270 (25.2%, 95% confidence interval [CI] 24.3-26.1) had a SARS-CoV-2 polymerase chain reaction test during the study period (range: 38.3% in Northern to 14.6% in Central-Eastern Europe). People from Northern Europe, women, those aged <40 years, those with CD4 cell count <350 cells/mm
Conclusions: We observed large heterogeneity in SARS-CoV-2 testing and positivity and a low proportion of hospital admissions and deaths across the regions of Europe.
(© 2024 The Authors. HIV Medicine published by John Wiley & Sons Ltd on behalf of British HIV Association.)